Cargando…

A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo

SARS-CoV-2, especially B.1.1.529/omicron and its sublineages, continues to mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity-enhanced soluble ACE2 (sACE2) is an alternative strategy that works by binding the SARS-CoV-2 S protein, acting as a ‘decoy’ to block the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Havranek, Brandon, Lindsey, Graeme Walker, Higuchi, Yusuke, Itoh, Yumi, Suzuki, Tatsuya, Okamoto, Toru, Hoshino, Atsushi, Procko, Erik, Islam, Shahidul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177734/ https://www.ncbi.nlm.nih.gov/pubmed/37173421 http://dx.doi.org/10.1038/s42003-023-04860-9

Ejemplares similares

An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo
por: Ikemura, Nariko, et al.
Publicado: (2022)

Computationally engineered ACE2 decoy binds with nanomolar affinity with the SARS-CoV-2 spike protein
por: Islam, Mohammad S., et al.
Publicado: (2022)

Engineering ACE2 decoy receptors to combat viral escapability
por: Arimori, Takao, et al.
Publicado: (2022)

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
por: Zhang, Lianghui, et al.
Publicado: (2022)

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
por: Zhang, Lianghui, et al.
Publicado: (2022)

Machine learning guided design of high affinity ACE2 decoys for SARS-CoV-2 neutralization
por: Chan, Matthew C., et al.
Publicado: (2021)

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
por: Chan, Kui K., et al.
Publicado: (2021)

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
por: Chan, Kui K., et al.
Publicado: (2020)

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
por: Zhang, Haoran, et al.
Publicado: (2022)

Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants
por: Tang, Haoneng, et al.
Publicado: (2022)

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
por: Lu, Mengjia, et al.
Publicado: (2023)

Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
por: Higuchi, Yusuke, et al.
Publicado: (2021)

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
por: Zhang, Lianghui, et al.
Publicado: (2022)

High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
por: Sims, Joshua J., et al.
Publicado: (2022)

Outsmarting SARS-CoV-2 by empowering a decoy ACE2
por: Sokolowska, Milena
Publicado: (2020)

A decoy mutant ACE2 designed to reduce COVID-19
por: Maishan, Mazharul, et al.
Publicado: (2022)

The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2
por: Procko, Erik
Publicado: (2020)

ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection
por: Ching, Krystal L., et al.
Publicado: (2022)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins
por: Conceicao, Carina, et al.
Publicado: (2020)

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
por: Du, Wenjuan, et al.
Publicado: (2022)

SARS-CoV-2 omicron spike simulations: broad antibody escape, weakened ACE2 binding, and modest furin cleavage
por: Jawaid, M. Zaki, et al.
Publicado: (2023)

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
por: Linsky, Thomas W., et al.
Publicado: (2020)

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
por: Tanaka, Shiho, et al.
Publicado: (2021)

Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2
por: Verstraete, Meghan M., et al.
Publicado: (2023)

Generation of enzymatically competent SARS‐CoV‐2 decoy receptor ACE2‐Fc in glycoengineered Nicotiana benthamiana
por: Castilho, Alexandra, et al.
Publicado: (2021)

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
por: Capraz, Tümay, et al.
Publicado: (2021)

Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model
por: Tada, Takuya, et al.
Publicado: (2023)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding
por: Lin, Sheng, et al.
Publicado: (2022)

Scanning the RBD-ACE2 molecular interactions in Omicron variant
por: Rath, Soumya Lipsa, et al.
Publicado: (2022)

Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
por: Zheng, Yun-zhe, et al.
Publicado: (2023)

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
por: Cele, Sandile, et al.
Publicado: (2021)

Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022)

Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
por: Inal, Jameel M.
Publicado: (2020)

The Sequence Basis for Selectivity of Ephrin-B2 Ligand for Eph Receptors and Pathogenic Henipavirus G Glycoproteins: Selective Ephrin-B2 Decoys for Nipah and Hendra Virus
por: Narayanan, Krishna K., et al.
Publicado: (2023)

Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
por: Lan, Jun, et al.
Publicado: (2022)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS‐CoV‐2
por: Kim, Jeonghwan, et al.
Publicado: (2022)

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
por: Chan, Kui K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fkjcad09arnfstec384m8ka2cv